NCT04733729: EPICOVIDEHA

Covid-19 in Hematological Malignancies

Recruiting now Last updated 29 May 2025

What this trial tests

trial in COVID-19 Infection in Hematological Malignancies Patients in 3,000 participants. Currently enrolling.

Timeline

1 March 2020

Primary endpoint
30 September 2022

31 December 2025

Quick facts

Lead sponsor	Sorveglianza Epidemiologica Infezioni Fungine Emopatie Maligne
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	3,000
Start date	1 March 2020
Primary completion	30 September 2022
Estimated completion	31 December 2025
Sites	6 locations across Italy

Conditions studied

• COVID-19 Infection in Hematological Malignancies Patients — all drugs for COVID-19 Infection in Hematological Malignancies Patients →

Sponsor

Sorveglianza Epidemiologica Infezioni Fungine Emopatie Maligne

Who can join

Adults 18 to 99, any sex, with COVID-19 Infection in Hematological Malignancies Patients. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The overall purpose of this project is to better understand the epidemiology of COVID-19 in patients with hematological malignancies (including hematopoietic stem cell transplant recipients) in the different European Countries. The results obtained will allow us to better know the prevalence of this complication in the different categories of patients with hematological malignancies (HMs). In order to attain the objectives previously described we will develop a multicentre, international, observational, retrospective and prospective study of consecutive cases of COVID-19 among HMs. There will be a clinical follow-up of the patients included in this study to observe the survival rate. Data collected form this study will be evaluated with a descriptive analysis.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA).
   Pagano L, Salmanton-García J, Marchesi F, Busca A, et al · · 2021 · cited 242× · PMID 34649563 · DOI 10.1186/s13045-021-01177-0
2. COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA.
   Pagano L, Salmanton-García J, Marchesi F, López-García A, et al · · 2022 · cited 80× · PMID 34748627 · DOI 10.1182/blood.2021014124
3. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey.
   Pagano L, Salmanton-García J, Marchesi F, Blennow O, et al · · 2022 · cited 71× · PMID 36126318 · DOI 10.1182/blood.2022017257
4. COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP.
   Busca A, Salmanton-García J, Corradini P, Marchesi F, et al · · 2022 · cited 65× · PMID 34749396 · DOI 10.1182/bloodadvances.2021005616
5. Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022.
   Salmanton-García J, Marchesi F, Farina F, Weinbergerová B, et al · · 2024 · cited 30× · PMID 38533127 · DOI 10.1016/j.eclinm.2024.102553
6. Improved Clinical Outcome of COVID-19 in Hematologic Malignancy Patients Receiving a Fourth Dose of Anti-SARS-CoV-2 Vaccine: An EPICOVIDEHA Report.
   Salmanton-García J, Marchesi F, Glenthøj A, Bilgin YM, et al · · 2022 · cited 27× · PMID 36310756 · DOI 10.1097/hs9.0000000000000789
7. Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry.
   Salmanton-García J, Marchesi F, Gomes da Silva M, Farina F, et al · · 2023 · cited 26× · PMID 37041967 · DOI 10.1016/j.eclinm.2023.101939
8. Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey.
   van Doesum JA, Salmanton-García J, Marchesi F, Di Blasi R, et al · · 2023 · cited 21× · PMID 37058479 · DOI 10.1182/bloodadvances.2022009578